Additionally, the study referenced a preclinical investigation that exhibited promising tumour suppression when the vaccine was combined with an anti‐programmed cell death protein 1 (PD‐1) monoclonal antibody, hinting at a potential future direction in therapy.67 This evidence concerns the gene PDCD1 and neoplasm.